These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30949704)

  • 1. Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing.
    Wicha WW; Prince WT; Lell C; Heilmayer W; Gelone SP
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii19-iii26. PubMed ID: 30949704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods.
    Zhang L; Wicha WW; Bhavnani SM; Rubino CM
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii27-iii34. PubMed ID: 30949708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
    File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
    BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired renal function and those requiring hemodialysis.
    Wicha WW; Marbury TC; Dowell JA; Crandon JL; Leister C; Ermer J; Gelone SP
    Pharmacotherapy; 2021 May; 41(5):451-456. PubMed ID: 33797776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin.
    Rodvold KA
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii2-iii4. PubMed ID: 30949709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
    Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
    File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
    Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis.
    Sawicki GS; Wicha WW; Hiley TS; Close NC; Gelone SP; Guico-Pabia CJ
    Clin Ther; 2024 Feb; 46(2):96-103. PubMed ID: 38195348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
    Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
    Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lefamulin: The First Systemic Pleuromutilin Antibiotic.
    Chahine EB; Sucher AJ
    Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired-hepatic function.
    Wicha WW; Marbury TC; Dowell JA; Crandon JL; Leister C; Ermer J; Gelone SP
    Pharmacotherapy; 2021 May; 41(5):457-462. PubMed ID: 33811377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
    Godfrey AR; Digiacinto J; Davis MW
    Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
    Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
    Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae.
    Wicha WW; Strickmann DB; Paukner S
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii11-iii18. PubMed ID: 30949707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of lefamulin for the treatment of community acquired bacterial pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2020 Apr; 21(6):629-636. PubMed ID: 31958020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.
    Lee D; Lim LA; Jang SB; Lee YJ; Chung JY; Choi JR; Kim K; Park JW; Yoon H; Lee J; Park MS; Park K
    Clin Ther; 2011 Dec; 33(12):2038-53. PubMed ID: 22129569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects.
    Upreti VV; Keung CF; Boulton DW; Chang M; Li L; Tang A; Hsiang BC; Quamina-Edghill D; Frevert EU; Lacreta FP
    Clin Drug Investig; 2013 May; 33(5):365-74. PubMed ID: 23549864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.